Course of Graves Disease in Interferon-Treated Patients With Chronic Hepatitis C Virus Infection and in Uninfected Patients

被引:2
|
作者
Minelli, Roberta [1 ]
Spagnoli, Francesca [1 ]
Marchesi, Elisabetta [1 ]
Venturi, Nicola [1 ]
Marina, Michela [1 ]
Orlandini, Alessandra [2 ]
Zardo, Marianna [1 ]
Ferrari, Carlo [2 ]
Ceresini, Graziano [3 ]
机构
[1] Azienda Osped Univ Parma, UOC Endocrinol, Dipartimento Med Clin & Sperimentale, Parma, Italy
[2] Azienda Osped Univ Parma, UOC Malattie Infett, Dipartimento Oncoematol Internist, Parma, Italy
[3] Azienda Osped Univ Parma, SS Endocrinol Geriatr, Dipartimento Med Clin & Sperimentale, Parma, Italy
关键词
Graves disease; HCV-hepatitis; interferon alfa therapy; INDUCED THYROID-DYSFUNCTION; CHRONIC VIRAL-HEPATITIS; ALPHA TREATMENT; THERAPY; AUTOIMMUNITY; AUTOANTIBODIES; ASSOCIATION;
D O I
暂无
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: The development of thyroid antibodies and the alteration of thyroid function are the most common disorders associated with interferon alfa therapy in individuals with chronic hepatitis C (CHC). In this study, we compared the course of Graves disease (GD) between patients diagnosed with CHC and treated with interferon alfa and uninfected patients. Methods: We retrospectively analyzed data from 39 GD patients (15 men and 24 women, group 1) affected by CHC and treated with interferon alfa and from 43 uninfected GD patients (19 men and 24 women, group 2) who were seen at our institution from 1999 to 2011. All GD patients were treated with methimazole (MMI). Daily dose of MMI, duration of MMI therapy, and remission rate were evaluated in both groups. Results: The daily dose of MMI was found to be lower in group 1 as compared with group 2 (9.74 +/- 5.94 mg/d vs 14.12 +/- 8.64 mg/d in group 1 vs group 2, respectively, P < 0.01). In addition, the duration of MMI treatment was found to be lower in group 1 as compared with group 2 (13.98 +/- 13.0 months vs 38.86 +/- 27.13 months in group 1 vs group 2, respectively; P < 0.01). The remission rate from GD was higher in the patients of group 1 in comparison with the patients of group 2 (87.17% vs 48.86% in group 1 vs group 2, respectively, P < 0.005). Conclusion: Altogether, our data demonstrate a more favorable course of GD in the patients with CHC treated with interferon alfa compared with GD occurring in the patients without CHC.
引用
收藏
页码:1173 / 1177
页数:5
相关论文
共 50 条
  • [1] Graves' disease in interferon-α-treated and untreated patients with chronic hepatitis C virus infection
    Minelli, R
    Coiro, V
    Valli, MA
    Finardi, L
    Di Secli, C
    Bertoni, R
    La Gioia, D
    Barilli, AL
    Ferrari, C
    Jotti, GS
    Delsignore, R
    JOURNAL OF INVESTIGATIVE MEDICINE, 2005, 53 (01) : 26 - 30
  • [2] Evolution of viral quasispecies in interferon-treated patients with chronic hepatitis C virus infection
    Hassoba, HM
    Bzowej, N
    Berenguer, M
    Kim, M
    Zhou, S
    Phung, Y
    Grant, R
    Pessoa, MG
    Wright, TL
    JOURNAL OF HEPATOLOGY, 1999, 31 (04) : 618 - 627
  • [3] Evolution of viral quasispecies in interferon-treated patients with chronic hepatitis C infection.
    Bzowej, NH
    Berenguer, M
    Pessoa, M
    Kim, M
    Fung, Y
    Wright, TL
    JOURNAL OF INVESTIGATIVE MEDICINE, 1999, 47 (02) : 46A - 46A
  • [4] Relevance of inapparent coinfection by hepatitis B virus in alpha interferon-treated patients with hepatitis C virus chronic hepatitis
    Zignego, AL
    Fontana, R
    Puliti, S
    Barbagli, S
    Monti, M
    Careccia, G
    Giannelli, F
    Giannini, C
    Buzzelli, G
    Brunetto, MR
    Bonino, F
    Gentilini, P
    JOURNAL OF MEDICAL VIROLOGY, 1997, 51 (04) : 313 - 318
  • [5] Long-term course of interferon-treated chronic hepatitis C
    Cammà, C
    Di Marco, V
    Lo Iacono, O
    Almasio, P
    Giunta, M
    Fuschi, P
    Vaccaro, A
    Fabiano, C
    Magrin, S
    Di Stefano, R
    Bonura, C
    Pagliaro, L
    Craxì, A
    JOURNAL OF HEPATOLOGY, 1998, 28 (04) : 531 - 537
  • [6] PREDICTIVE VALUE OF HEPATITIS-C VIRUS DENSITY ANALYSIS FOR RELAPSE IN INTERFERON-TREATED CHRONIC HEPATITIS-C PATIENTS
    KANTO, T
    HAYASHI, N
    TAKEHARA, T
    HAGIWARA, H
    MITA, E
    KASAHARA, A
    FUSAMOTO, H
    KAMADA, T
    HEPATOLOGY, 1994, 20 (04) : A157 - A157
  • [7] Hepatitis G virus infection in patients with hepatitis C treated with interferon
    Salas, E
    GonzalezVilchez, J
    Rebollo, J
    Pinar, A
    Martin, J
    Jimenez, M
    Herrerias, JM
    HEPATOLOGY, 1996, 24 (04) : 1784 - 1784
  • [9] Characteristics of Graves' Disease in a Cohort of Chronic Hepatitis C Patients Treated With Interferon-alpha and Ribavirin
    Tran, Huy A.
    Reeves, Glenn Em
    JOURNAL OF ENDOCRINOLOGY AND METABOLISM, 2011, 1 (01) : 14 - 20
  • [10] Prevalence of Bacterial Infection in Patients with Chronic Hepatitis C Treated and not Treated with Interferon
    El-Kholy, Iman. M. A.
    Abdelaziz, M. H.
    Abdelsalam, S. W.
    EGYPTIAN JOURNAL OF BOTANY, 2016, 56 (01): : 269 - 282